Contrast-induced nephropathy: pharmacological prophylaxis.

[1]  Y. Li,et al.  [Nephrotoxicity of high- and low-osmolar contrast media: Protective role of fosinopril or telmisartan in a rat model]. , 2000, Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences.

[2]  E. Kline-Rogers,et al.  Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. , 2005, The American journal of medicine.

[3]  K. Shojania,et al.  Is acetylcysteine effective in preventing contrast-related nephropathy? A meta-analysis. , 2004, The American journal of medicine.

[4]  D. Greenwood,et al.  Ascorbic Acid Prevents Contrast-Mediated Nephropathy in Patients With Renal Dysfunction Undergoing Coronary Angiography or Intervention , 2004, Circulation.

[5]  C. McCulloch,et al.  Theophylline for the prevention of radiocontrast nephropathy: a meta-analysis. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[6]  P. McLaughlin,et al.  N-acetylcysteine reduces contrast-associated nephropathy but not clinical events during long-term follow-up. , 2004, American heart journal.

[7]  A. Levin,et al.  A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect. , 2004, American heart journal.

[8]  A. Colombo,et al.  N-acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity , 2004 .

[9]  M. Tonelli,et al.  Systematic review of the impact of N-acetylcysteine on contrast nephropathy. , 2004, Kidney international.

[10]  C. Poole,et al.  N-acetylcysteine for the prevention of radiocontrast induced nephropathy: a meta-analysis of prospective controlled trials. , 2004, Journal of the American Society of Nephrology : JASN.

[11]  B. Krämer,et al.  The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. , 2004, Journal of the American Society of Nephrology : JASN.

[12]  E. Schwammenthal,et al.  Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature. , 2004, European heart journal.

[13]  A. Colombo,et al.  Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. , 2004, European heart journal.

[14]  B. Altun,et al.  Radiocontrast-induced nephrotoxicity and urinary alpha-glutathione S-transferase levels: Effect of amlodipine administration , 2004, International Urology and Nephrology.

[15]  B. Jaber,et al.  Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[16]  P. O'Malley,et al.  Meta-analysis of randomized clinical trials on the usefulness of acetylcysteine for prevention of contrast nephropathy. , 2003, The American journal of cardiology.

[17]  D. Hilleman,et al.  Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography. , 2003, American heart journal.

[18]  J. Morrow,et al.  The effect of N-acetylcysteine on renal function, nitric oxide, and oxidative stress after angiography. , 2003, Kidney International.

[19]  G. Stone,et al.  Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. , 2003, JAMA.

[20]  F. Markowetz,et al.  Acetylcysteine for prevention of contrast nephropathy: meta-analysis , 2003, The Lancet.

[21]  A. Wragg,et al.  A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. , 2003, Journal of the American College of Cardiology.

[22]  M. Seyfarth,et al.  Effectiveness of theophylline prophylaxis of renal impairment after coronary angiography in patients with chronic renal insufficiency. , 2003, The American journal of cardiology.

[23]  S. Sdringola,et al.  Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast , 2003, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[24]  Chi‐Hang Lee,et al.  Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. , 2003, JAMA.

[25]  S. Heyman,et al.  N-acetylcysteine ameliorates renal microcirculation: studies in rats. , 2003, Kidney international.

[26]  H. Miller,et al.  Effects of an Acute Dose of L-Arginine during Coronary Angiography in Patients with Chronic Renal Failure , 2003, American Journal of Nephrology.

[27]  S. Fishbane,et al.  A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. , 2002, Kidney international.

[28]  S. Allaqaband,et al.  Prospective randomized study of N‐acetylcysteine, fenoldopam, and saline for prevention of radiocontrast‐induced nephropathy , 2002, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[29]  N. Sinha,et al.  The role of theophylline in contrast-induced nephropathy: a case-control study. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[30]  K. Shyu,et al.  Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. , 2002, Journal of the American College of Cardiology.

[31]  D. Hunter,et al.  Using a dopamine type 1A receptor agonist in high-risk patients to ameliorate contrast-associated nephropathy. , 2002, AJR. American journal of roentgenology.

[32]  B. Villari,et al.  Acetylcysteine and contrast agent-associated nephrotoxicity. , 2002, Journal of the American College of Cardiology.

[33]  M. Classen,et al.  Effect of theophylline on contrast material-nephropathy in patients with chronic renal insufficiency: controlled, randomized, double-blinded study. , 2002, Radiology.

[34]  J. Tumlin,et al.  Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy. , 2002, American heart journal.

[35]  Samin K. Sharma,et al.  Changing trends in incidence and predictors of radiographic contrast nephropathy after percutaneous coronary intervention with use of fenoldopam. , 2002, The American journal of cardiology.

[36]  Douglas Losordo,et al.  Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). , 2002, The American journal of cardiology.

[37]  Chen Km,et al.  Radiographic contrast media induced nephropathy: experimental observations and the protective effect of calcium channel blockers , 2001 .

[38]  N. Shammas,et al.  Aminophylline does not protect against radiocontrast nephropathy in patients undergoing percutaneous angiographic procedures. , 2001, The Journal of invasive cardiology.

[39]  D. Weaver,et al.  Use of fenoldopam to prevent radiocontrast nephropathy in high‐risk patients , 2001, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[40]  H. Izzedine,et al.  Effect of N-acetylcysteine on serum creatinine level. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[41]  M. Classen,et al.  Reduced incidence of radiocontrast-induced nephropathy in ICU patients under theophylline prophylaxis: a prospective comparison to series of patients at similar risk , 2001, Intensive Care Medicine.

[42]  Y. Peng,et al.  Nephrotoxicity of high- and low-osmolar contrast media: The protective role of amlodipine in a rat model , 2000, Acta radiologica.

[43]  W Zidek,et al.  Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. , 2000, The New England journal of medicine.

[44]  M. Rudnick,et al.  Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism. , 2000, Kidney international.

[45]  U. Mödder,et al.  Prostaglandin E1: a new agent for the prevention of renal dysfunction in high risk patients caused by radiocontrast media? PGE1 Study Group. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[46]  M. Gotsman,et al.  The renal effect of low-dose dopamine in high-risk patients undergoing coronary angiography. , 1999, Journal of the American College of Cardiology.

[47]  R. Luther,et al.  The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects. , 1999, Critical care medicine.

[48]  G. Bakris,et al.  Renal hemodynamics in radiocontrast medium-induced renal dysfunction: A role for dopamine-1 receptors. , 1999, Kidney international.

[49]  T. Risler,et al.  Prevention of radiocontrast-media-induced nephropathy in patients with pre-existing renal insu ffi ciency by hydration in combination with the adenosine antagonist theophylline , 1999 .

[50]  M. Tariq,et al.  N-acetylcysteine attenuates cyclosporin-induced nephrotoxicity in rats. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[51]  W. O’Neill,et al.  A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy ☆: Results of the P.R.I.N.C.E. study , 1999 .

[52]  M. Leon,et al.  Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency. , 1999, The American journal of cardiology.

[53]  A. Więcek,et al.  The nonselective adenosine antagonist theophylline does prevent renal dysfunction induced by radiographic contrast agents. , 1998, Journal of nephrology.

[54]  C. Dmuchowski,et al.  Effect of dopamine on renal function after arteriography in patients with pre-existing renal insufficiency. , 1998, The American surgeon.

[55]  E. Bates,et al.  Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[56]  N. Sinha,et al.  Use of dopamine in prevention of contrast induced acute renal failure--a randomised study. , 1996, International journal of cardiology.

[57]  M. Cova,et al.  Dose effect of nitrendipine on urinary enzymes and microproteins following non-ionic radiocontrast administration. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[58]  T. Skau,et al.  Does prophylactic treatment with felodipine, a calcium antagonist, prevent low-osmolar contrast-induced renal dysfunction in hydrated diabetic and nondiabetic patients with normal or moderately reduced renal function? , 1996, Scandinavian journal of urology and nephrology.

[59]  T. Wiegmann,et al.  Effects of Misoprostol on Contrast-Induced Renal Dysfunction. , 1995, American journal of therapeutics.

[60]  B. Memoli,et al.  Early effects of contrast media on renal hemodynamics and tubular function in chronic renal failure. , 1995, Journal of the American Society of Nephrology : JASN.

[61]  G. Taylor,et al.  Nephrotoxicity from contrast media: attenuation with theophylline. , 1995, Radiology.

[62]  A. P. Shapiro,et al.  The Effect of Prophylactic Nifedipine on Renal Function in Patients Administered Contrast Media , 1995, Pharmacotherapy.

[63]  J. D'Elia,et al.  Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents. , 1994, The New England journal of medicine.

[64]  P. Huppert,et al.  Adenosine antagonist theophylline prevents the reduction of glomerular filtration rate after contrast media application. , 1994, Kidney international.

[65]  P. Kurnik,et al.  Dopamine and renal blood flow in radiocontrast-induced nephropathy in humans. , 1993, Renal failure.

[66]  V. Bernhard,et al.  Contrast-induced nephrotoxicity: the effects of vasodilator therapy. , 1992, The Journal of surgical research.

[67]  C. Romanowski,et al.  The use of theophylline, an adenosine antagonist in the prevention of contrast media induced nephrotoxicity. , 1992, The British journal of radiology.

[68]  K. Margulies,et al.  Induction and prevention of radiocontrast-induced nephropathy in dogs with heart failure. , 1990, Kidney international.

[69]  N. Patel,et al.  Renal functional response to dopamine during and after arteriography in patients with chronic renal insufficiency. , 1990, Radiology.

[70]  A. Testa,et al.  Randomised prospective study on renal effects of two different contrast media in humans: protective role of a calcium channel blocker. , 1990, Nephron.

[71]  A. Wenning,et al.  Prevention of radiocontrast-media-induced nephrotoxicity by the calcium channel blocker nitrendipine: a prospective randomised clinical trial. , 1989, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[72]  P. Cacoub,et al.  No evidence for protective effects of nifedipine against radiocontrast-induced acute renal failure. , 1988, Clinical nephrology.

[73]  J. Pourrat,et al.  Renal side effect of nifedipine , 1984, Clinical cardiology.